Utilization of remote monitoring among patients receiving cardiac resynchronization therapy and comparison between Asia and the Americas.

Abstract

Listen

Translate article

There is increasing momentum in application of digital solutions in medicine to improve patient outcomes and reduce global health inequities.1,2 Remote monitoring (RM) of patients with cardiac implantable electronic devices received a Class 1 recommendation in 2015 in the United States.3 However, adoption varies by device type (eg, pacemakers less frequently) and patient condition, possibly because sicker patients and/or those with more complex devices are perceived to have the most to gain. Cardiac resynchronization therapy (CRT) is the most complex cardiac implantable electronic device, and “nonresponders” (CRT-NR) have one of the poorest prognoses among heart failure patients.